WASHINGTON — The Centers for Medicare and Medicaid Services proposed a major payment bump for hospitals administering the cutting-edge gene therapies known as CAR-T treatments late Monday.
It’s a direct response to longstanding criticisms from the pharmaceutical industry, patient advocates, and hospitals that said Medicare’s subpar reimbursement rates for the new therapies — which can have list prices upward of $450,000 per patient — forced hospitals to choose between losing money or declining to offer the therapies at all.
About the Author Reprints
I hope Gilead and Novartis would agree to set the price for Yescarta and Kymrish as close as possible to say within $500 of each other to get around this average nonsense!